Abilify Maintena (Aripiprazole Extended-Release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 1, 2014 Category: Drugs & Pharmacology Source Type: news
Shrink Rap News: The surprisingly high cost of Abilify
Read the full story on MD Consult:
Shrink Rap News: The surprisingly high cost of Abilify (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - November 17, 2014 Category: Journals (General) Source Type: news
Serotonin syndrome masked by concomitant ingestion of Zoloft with benzodiazepine in suicide attempt in a young healthy male -
This case report discusses the history and management of a schizophrenic patient, a 18-year-old man, who had taken a massive overdose of clonazepam, abilify, depakote, zoloft and seroquel altogether. After discontinuation of these drugs and administration ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - November 15, 2014 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
FDA Approves Drug With Digital Ingestion Tracking System
Aripiprazole tablets have embedded sensors so patients, physicians can track medication ingestion (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 11, 2014 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Nursing, Pharmacy, Psychiatry, Institutional, Source Type: news
What Are the Potential Side Effects of...
Abilify - generic name aripiprazole - is an atypical antipsychotic medication sometimes prescribed to treat schizophrenia and psychotic features of bipolar and schizoaffective disorders. People taking Abilify should be aware of the potential side effects. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - October 7, 2014 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news
Alkermes submits new drug application for aripiprazole to treat Schizophreni
The US Food and Drug Administration (FDA) has received a new drug application (NDA) from Ireland-based Alkermes for its aripiprazole lauroxil to treat schizophrenia. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 25, 2014 Category: Pharmaceuticals Source Type: news
Top 100 Most Prescribed, Top-Selling DrugsTop 100 Most Prescribed, Top-Selling Drugs
The hypothyroid drug levothyroxine continues to be the most prescribed drug in the US and the antipsychotic aripiprazole continues to have the highest sales. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 1, 2014 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits
Rather this is an advance that will help control psychotic episodes in patients in need. Without reimbursement, uptake of aripiprazole will be slow and it will be underutilized. This can?t happen. This drug, if properly used, provides a way to help to reduce violent crimes in our society. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 18, 2014 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Top 100 Most Prescribed, Top Selling DrugsTop 100 Most Prescribed, Top Selling Drugs
The thyroid drug levothyroxine continues to be the most prescribed drug in the United States, and the antipsychotic aripiprazole continues to have the most sales, new data indicate. Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 13, 2014 Category: Drugs & Pharmacology Tags: Family Medicine/Primary Care News Source Type: news
OCD and Atypical Antipsychotics
While the frontline treatment for obsessive-compulsive disorder continues to be Exposure and Response Prevention (ERP) therapy, many who suffer from obsessive-compulsive disorder also appear to be helped by medication. Often the combination of ERP therapy and medication, typically high doses of selective serotonin reuptake inhibitors (SSRIs, also prescribed for depression) seems to be particularly helpful.
This was the route taken with my son Dan when his OCD was severe. He also was taking a benzodiazepine. He was making progress, slowly but surely, in his fight against OCD but was subsequently prescribed an atypical antip...
Source: Psych Central - May 8, 2014 Category: Psychiatry Authors: Janet Singer Tags: Atypical Antipsychotics Disorders Family General Medications Obsessive-Compulsive Disorder Parenting Treatment Antipsychotic Side Effects Anxiety Erp exposure and response prevention therapy Exposure Therapy Neuroleptics Select Source Type: news
Alkermes reports positive Phase III trial results of schizophrenia drug aripiprazole lauroxil
Ireland-based biopharmaceutical firm Alkermes has reported positive topline results from a randomised, double-blind, placebo-controlled Phase III clinical trial of its new, long-acting injectable antipsychotic agent aripiprazole lauroxil in patients … (Source: Drug Development Technology)
Source: Drug Development Technology - April 9, 2014 Category: Pharmaceuticals Source Type: news
Positive Topline Results for New Schizophrenia DrugPositive Topline Results for New Schizophrenia Drug
Once-monthly treatment with aripiprazole lauroxil, a new injectable, long-acting antipsychotic, significantly reduces positive and negative symptoms in schizophrenia patients. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 8, 2014 Category: Psychiatry Tags: Psychiatry News Source Type: news
Lundbeck And Otsuka Launch Abilify Maintena In Europe
H. Lundbeck A/S and Otsuka Pharmaceutical Europe Ltd. announced the European launch of Abilify Maintena (aripiprazole) following the approval by the European Commission last November 2013. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 19, 2014 Category: Pharmaceuticals Source Type: news
Health Canada approves Otsuka and Lundbeck's once-monthly Abilify Maintena
Health Canada has issued a notice of compliance for Otsuka and Lundbeck's Abilify Maintena, an intramuscular (IM) once-monthly injectable formulation, for the maintenance treatment of schizophrenia in stabilised adult patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 14, 2014 Category: Pharmaceuticals Source Type: news
Using Aripiprazole in Major Depressive DisorderUsing Aripiprazole in Major Depressive Disorder
The doses of aripiprazole required by patients in clinical practice are assessed in this study. Medscape Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2013 Category: Consumer Health News Tags: Psychiatry Viewpoint Source Type: news
